Test Price
2,800 AED✅ Home Collection Available
JAK2 Gene Mutation NGS Test for Acute Myelogenous Leukemia (AML) in UAE | 2,800 AED
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Certified Next-Generation Sequencing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection. Available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by a Consultant Medical Genetics specialist.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This Next-Generation Sequencing (NGS) analysis detects all coding-region mutations in the JAK2 gene associated with Acute Myelogenous Leukemia (AML), guiding precise subtyping and targeted therapy selection. The assay covers all coding exons (1–25) including splice sites, delivering comprehensive genomic insight for personalized oncology management.
| Feature | Our JAK2 Full Gene NGS | Closest Alternative (JAK2 V617F PCR) |
|---|---|---|
| Methodology | Next-Generation Sequencing (Illumina) | Allele-Specific PCR / Sanger |
| Coverage | All coding exons (1–25) + splice sites | Exon 14 V617F mutation only |
| Analytical Sensitivity | ≤1% variant allele frequency | 5–10% (risk of false-negative) |
| Turnaround Time | 3–4 Weeks | 1–2 Weeks |
| Clinical Applications | AML subtype confirmation, JAK inhibitor eligibility, prognosis stratification | Primary diagnosis of polycythemia vera / essential thrombocythemia |
Physician Insight & Safety Protocols
“A comprehensive JAK2 gene analysis via NGS provides critical insights into AML pathogenesis. This information becomes most valuable when your hematologist integrates it with your complete clinical picture including bone marrow histology, cytogenetics, and blood counts. Genetic test results should always guide, not replace, your ongoing treatment discussions with your specialist.”
– Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Clinical Advisory & Safety Precautions
- Do not discontinue prescribed medications without direct physician consultation.
- Recent blood transfusion (within 2 weeks) may affect DNA yield; reschedule accordingly.
- Active chemotherapy or radiation may compromise sample quality; discuss optimal timing with your oncologist.
- Absolute contraindication: none for venipuncture; relative contraindication: severe anemia requiring immediate transfusion.
Patient Exclusion Criteria & Contraindications
Emergency Red Flags
Seek immediate medical attention if you experience sudden bone pain, unexplained bleeding, high fever, or severe fatigue – these may indicate disease progression. Contact your physician or local ER.
Patient FAQ & Clinical Guidance
1. What is the purpose of JAK2 mutation testing in AML?
This NGS test identifies JAK2 gene mutations to confirm AML subtype, guide targeted therapy, and assess prognosis. A positive JAK2 result may indicate eligibility for JAK inhibitors like ruxolitinib, often combined with standard chemotherapy. It also helps in distinguishing de novo AML from myeloproliferative neoplasms that progress to leukemia.
2. How should I prepare for the sample collection?
You require a genetic counseling session to chart your family history and understand implications. The actual sample collection requires a standard blood draw or buccal swab, with no fasting necessary. Bring a list of current medications and prior medical records to the counseling session. If extracting DNA from saliva or buccal cells, avoid eating, drinking, or smoking for 30 minutes before collection.
3. What does a positive JAK2 mutation result mean?
A JAK2 mutation indicates a myeloid neoplasm that may benefit from JAK inhibitor therapy, but clinical correlation is essential. The exact variant (e.g., V617F, exon 12, or other rare mutations) will be reported with its significance. Your oncologist will integrate this with bone marrow blast count and cytogenetics to finalize the AML diagnosis and treatment plan. A negative result does not rule out AML – other genetic drivers may be present.
4. Will my insurance cover this NGS test?
Coverage varies by insurance provider and policy. We assist with direct billing verification via WhatsApp. Contact us at +971 54 548 8731 to confirm your coverage before scheduling the test.
5. How long does it take to receive results?
The turnaround time is 3–4 weeks from sample receipt at the laboratory. This duration ensures complete sequencing, bioinformatics analysis, and clinical interpretation by our genetics team.
UAE Regulatory & Data Privacy Adherence
All genetic testing and data handling at DNA Labs UAE strictly comply with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – governing the collection, processing, and storage of your genetic and health information.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – ensuring secure digital health data exchange.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – safeguarding patient consent and clinical safety throughout the testing pathway.
Your genomic data is encrypted, access-restricted, and used solely for diagnostic purposes with your explicit written consent.
Clinical & Logistical Metadata
| Test Name | JAK2 Gene Mutation NGS Test for Acute Myelogenous Leukemia (AML) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood or Buccal Swab |
| Methodology Used | Next-Generation Sequencing (Illumina) |
| ICD-10-CM Code | C92.00 |
| LOINC Code | 92806-5 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians